Our mission is the development of novel therapeutics for the treatment of patients with solid tumors and hematologic malignancies that express the highly prevalent MUC1 cancer target. Genus has identified the “Achilles Heel” of MUC1, the MUC1-C subunit, and is developing agents that target this oncogenic transmembrane protein. Our lead drug candidate GO-203, a peptide that specifically targets the MUC1-C cytoplasmic domain, is currently under evaluation in a Phase 2 clinical trial in combination with decitabine for patients with relapsed/refractory acute myeloid leukemia (AML) at Harvard’s Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. Genus is also advancing a portfolio of antibodies against the non-shed MUC1-C extracellular domain, which includes humanized forms for therapeutic approaches such as antibody-drug conjugates (ADCs), antibody-dependent cell-mediated cytotoxicity (ADCC), bispecifics and CAR-T.
“We believe our broad and unique portfolio of first-in-class MUC1-C therapeutics, specifically agents that target the MUC1-C cytoplasmic domain and antibodies against the non-shed MUC1-C extracellular domain, represents multiple approaches for the treatment of the many carcinomas and hematologic malignancies diagnosed each year that aberrantly overexpress the MUC1-C oncoprotein”
–Chairman & CEO Nick Pontikes